CancerNCT00366717
Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
An observational study of Cancer and Cytomegalovirus, run by Mackay Memorial Hospital at 1 site in Taiwan.
Trial summary
Cytomegalovirus (CMV) infects most of the world population. This study is to understand if chemotherapy will increase the chance of reactivating CMV. The results may help us in determining when treatment is needed and perhaps Why is it needed. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Cancer, Cytomegalovirus
- How many people
- 20 participants
- Where
- 1 siteTaiwan
- Study dates
- Jun 2005to Jan 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- clinical diagnosis of any cancer
- chemotherapy is needed for more than 6 months
- age>20 years old
Who cannot join
- those who do not agree to participate
Trial locations and contacts
1 site in 1 country.
About this study
Cytomegalovirus (CMV) infects most of the world population. This study is to understand if chemotherapy will increase the chance of reactivating CMV. The results may help us in determining when treatment is needed and perhaps Why is it needed.
Read the detailed description
Despite CMV reactivation has been clearly described in patients underwent transplantation, this phenomenon has not been studied in patients undergoing chemotherapy. Our purpose is to understand if CMV number increases in monocytic leukocytes during chemotherapy and how is the host response to that changes.
Virus load will be studied by quantitative PCR, host response will be studied by measuring patient's anti-CMV IgG, CMV-associated symptoms, serum IFN-r and TNF-a.
- Conditions
- Cancer, Cytomegalovirus
- Keywords
- Cancer under chemotherapy
- Medical subject headings
- Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2006 (estimated)
- Study startJun 2005
- Study completionJan 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
- Enrolment
- 20 participants
Sponsor and investigators
- Lead sponsor
- Mackay Memorial Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Yen-Ta Lu, MD, PhD., Principal investigator, Mackay Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00366717
- Sponsor's protocol ID
- MMH-I-S-144
- Status last verified
- Jan 2006
- First submitted
- 18 Aug 2006
- Last updated
- 21 Aug 2006
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy
- ClinicalTrials.gov ID
- NCT00366717
- Acronym / sponsor ID
- MMH-I-S-144
- Conditions
- Cancer, Cytomegalovirus
- Keywords
- Cancer under chemotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants
- Lead sponsor
- Mackay Memorial HospitalUniversity, hospital or other
- Study start
- Jun 2005
- Study completion
- Jan 2006
- First posted
- 21 Aug 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cytomegalovirus (CMV) infects most of the world population. This study is to understand if chemotherapy will increase the chance of reactivating CMV. The results may help us in determining when treatment is needed and perhaps Why is it needed.
Detailed description
Despite CMV reactivation has been clearly described in patients underwent transplantation, this phenomenon has not been studied in patients undergoing chemotherapy. Our purpose is to understand if CMV number increases in monocytic leukocytes during chemotherapy and how is the host response to that changes.
Virus load will be studied by quantitative PCR, host response will be studied by measuring patient's anti-CMV IgG, CMV-associated symptoms, serum IFN-r and TNF-a.
Study design
- Observational model
- Defined population
- Time perspective
- Prospective
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- clinical diagnosis of any cancer
- chemotherapy is needed for more than 6 months
- age>20 years old
Key exclusion criteria (1 listed)
- those who do not agree to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2006.
- Home page of Mackay Memorial HospitalLink provided by the sponsor.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yen-Ta Lu, MD, PhD. principal investigator
Mackay Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Cytomegalovirus, run by Mackay Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Aug 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2006.